The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study

dc.authoridTASCI, ILKER/0000-0002-0936-2476
dc.authoridDagdelen, Selcuk/0000-0002-0513-1750
dc.authoridsahin, mustafa/0000-0002-4718-0083
dc.authoridDemirci, Ibrahim/0000-0003-0498-3115
dc.authoridSatman, Ilhan/0000-0001-8613-1797
dc.authoridSonmez, Alper/0000-0002-9309-7715
dc.authoridcelik, osman/0000-0003-2131-2866
dc.authorwosidTASCI, ILKER/B-7556-2009
dc.authorwosidDagdelen, Selcuk/A-9432-2017
dc.authorwosidCelik, Osman/KLZ-6766-2024
dc.authorwosidCaglayan, Murat/AGY-9057-2022
dc.authorwosidsahin, mustafa/AAH-3394-2019
dc.authorwosidUstun, Yaprak/KFQ-9767-2024
dc.authorwosidDemirci, Ibrahim/AAR-3277-2020
dc.contributor.authorSahin, Mustafa
dc.contributor.authorHaymana, Cem
dc.contributor.authorDemirci, Ibrahim
dc.contributor.authorTasci, Ilker
dc.contributor.authorRifat, Emral
dc.contributor.authorUnluturk, Ugur
dc.contributor.authorSatman, Ilhan
dc.date.accessioned2024-08-04T20:50:13Z
dc.date.available2024-08-04T20:50:13Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality in thyroid cancer patients with COVID-19 infection. Design and methods We included a cohort of patients with thyroid cancer with PCR-confirmed COVID-19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID-19 disease. Results We evaluated 388 COVID-19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender-matched 388 COVID-19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non-cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID-19 disease in our patient group. Conclusions Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID-19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.en_US
dc.identifier.doi10.1111/cen.14486
dc.identifier.endpage637en_US
dc.identifier.issn0300-0664
dc.identifier.issn1365-2265
dc.identifier.issue4en_US
dc.identifier.pmid33872399en_US
dc.identifier.scopus2-s2.0-85104961748en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage628en_US
dc.identifier.urihttps://doi.org/10.1111/cen.14486
dc.identifier.urihttps://hdl.handle.net/11616/99902
dc.identifier.volume95en_US
dc.identifier.wosWOS:000646151100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofClinical Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectmortalityen_US
dc.subjectradioactive iodine therapyen_US
dc.subjectthyroid canceren_US
dc.titleThe clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide studyen_US
dc.typeArticleen_US

Dosyalar